学校编码: 10384 学 号: 32720131150559

分类号_____密级____

UDC____

のたう

硕士学位论文

呼吸道合胞病毒感染动物模型的建立 及应用

Establishment and Application of Respiratory Syncytial

詹炉停

Virus Animal Model

指导教师姓名:郑子峥 助理教授 专业名称:流行病与卫生统计学 论文提交日期:2016年4月日 论文答辩时间:2016年5月日 学位授予日期:2016年月日

答辩委员会主席: _____ 何水珍____

评 阅 人:_____

2016年5月

厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成 果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均 在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学 术活动规范(试行)》。

 另外,该学位论文为(
)课题(组)的

 研究成果,获得(
)课题(组)经费或实验室的

 资助,在(
)实验

 室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,

未有此项声明内容的,可以不作特别声明。)

声明人 (签名): 詹於傳 2016年 5月 23日

厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办 法》等规定保留和使用此学位论文,并向主管部门或其指定机构送交 学位论文(包括纸质版和电子版),允许学位论文进入厦门大学图书 馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国 博士、硕士学位论文共建单位数据库进行检索,将学位论文的标题和 摘要汇编出版,采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于:

()1.经厦门大学保密委员会审查核定的保密学位论文,于 年 月 日解密,解密后适用上述授权。

()2.不保密,适用上述授权。

(请在以上相应括号内打"√"或填上相应内容。保密学位论文应 是已经厦门大学保密委员会审定过的学位论文,未经厦门大学保密委 员会审定的学位论文均为公开学位论文。此声明栏不填写的,默认为 公开学位论文,均适用上述授权。)

声明人 (签名): 虎吟傳 2016年 5月23日

摘	要	•••••••••••••••••••••••••••••••••••••••	····· I
Ab	stract	,	····III
缩	略词:		····VI
第·	一章 ī	前 言	1
1	呼呀	Q道合胞病毒概述 ······	1
	1.1	呼吸道合胞病毒流行病学分析及临床症状	1
	1.2	呼吸道合胞病毒病毒学背景	3
	1.3	呼吸道合胞病毒基因组结构及编码蛋白性质功能	3
	1.4	呼吸道合胞病毒复制周期	6
	1.5	呼吸道合胞病毒的宿主免疫应答	6
2	RSV	✓ 感染动物模型 ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯	8
	2.1	棉鼠模型 ·····	8
	2.2	小鼠模型	9
	2.3	裸鼠模型	10
	2.4	其他模型	10
3	呼呀	Q道合胞病毒疾病疫苗 ······	10
	3.1	灭活疫苗(FI-RSV) ······	10
	3.2	减毒活疫苗	11
	3.3	亚单位疫苗	11
	3.4	核酸疫苗	12
	3.5	病毒载体疫苗	12
4	呼呀	及道合胞病毒感染的预防与抗病毒的治疗	12
5	本研	¶究的思路、目的及意义 ······	13
第二	二章,	材料与方法	15

1	材料	· 15
1.1	主要仪器	· 15
1.2	2 主要试剂、耗材及实验动物	· 16
1.3	3 实验用溶液及培养基配制	· 17
2	实验方法 ······	· 19
2.1	常规细胞生物学实验方法	· 19
2.2	2 RSV 病毒实验学方法	• 19
2.3	3 RSV 免疫学相关实验方法	· 21
2.4	↓ 小鼠 RSV 感染实验方法	· 22
2.5	5 RSV 抗体在小鼠的预防性评估实验	· 22
3	数据处理及统计学分析	· 23
笛二音	告 结甲与公托	24
第二 4		24
1	RSV 高致病性病毒的制备	· 24
1.1	BALB/c小鼠体内 RSV 适应性病毒的制备	· 24
1.2	2 RSV 高滴度病毒的的制备	· 25
1.3	3 RSV 的标准化病毒制备	· 27
2	RSV 感染不同周龄 BALB/c 小鼠模型的建立	· 28
2.1	感染后小鼠一般情况	· 28
2.2	2 体重监测	· 29
2.3	3 鼻腔病毒滴度检测 ······	· 30
2.4	肺组织病毒滴度检测	· 31
2.5	5 肺组织病理学检测 ······	· 32
2.6	5 免疫组织化学染色检测肺组织病毒 ······	· 34
3	裸鼠 RSV 感染模型的建立	· 37
3.1	小鼠一般情况及体重变化	· 38
3.2	2 鼻内病毒复制的比较 ······	· 39
3.3	3 肺内病毒复制的比较 ······	· 40
3.4	↓ 肺组织病理学检测	· 41
3.5	5 肺组织免疫组织化学检测	· 42

4	BA	LB/c 小鼠 RSV 感染模型的应用	•••• 44
2	4.1	小鼠一般情况及体重监测	44
2	4.2	鼻内病毒复制检测	45
2	4.3	肺内病毒复制检测	46
2	4.4	肺组织病理学变化	47
2	4.5	免疫组织化学肺内抗原检测	49
第四	軍章	讨论	··· 52
1	RS	V 高滴度病毒制备是 RSV 小鼠模型建立的前提	52
2	BA	LB/c不同周龄小鼠感染模型建立的意义	52
3	裸目	鼠感染模型建立有助于研究 RSV 感染固有免疫作用	53
4	利用	用不同周龄 BALB/c 小鼠对高中和抗体 5C4 的预防性评估…	•••• 54
5	建	立多种动物模型的必要性	54
第王	章	小结与展望	56
1	小丝	结	56
2	展望	望	57
参考	⋚ 文南	献······	58
在核	交期问	间科研成果	72
致谚	H		73

Contents

1	Abtrac	t in Chinese ······	······ I
1	Abstra	ct in English······	······ III
1	Abbrev	viation ·····	····· VI
	Chapte	r 1 Preface ·····	1
	1 O	verview of Respiratory snycytial virus ······	1
	1.1	Epidemiology and clinical symptoms of RSV	1
	1.2	Viral backgroud of RSV ······	3
	1.3	The genome and proteins of RSV	3
	1.4	Replication cycle of RSV	6
	1.5	Immune response induced by RSV	6
	2 A1	nimal model of RSV ·····	8
	2.1	Cotton rat model ······	8
	2.2	BALB/c mice model ·····	9
	2.3	Nude mice model ·····	
	2.4	Others	
	3 R	SV vaccines ·····	
	3.1	Formalin invactivated vaccines (FI-RSV)	
	3.2	Live-attenuated vaccines	11
	3.3	Subunit vaccines ·····	11
	3.4	Gene vaccines ·····	12
	3.5	Virus vetor vaccines ·····	12
	4 Pr	ophylactics and therapeutics of RSV	12
	5 G	oal and Significance of the Thesis	13
	Chanta	n ? Matarial and Mathada	
	Cnapte	er 2 iviaterial and ivietnous	
	1 M	aterials	15

	1.1	Instruments ·····	15
	1.2	Reagents, supplies and animals	16
	1.3	Solutions and medium	17
2	M	lethod ·····	19
	2.1	Cell Biology Methods	19
	2.2	Methods of RSV virus	19
	2.3	Immunodetection of RSV	21
	2.4	RSVInfection methods on mice of RSV	22
	2.5	Methods for prophylatic efficacy of mAb	22
3	St	atistical Analysis	23
Cha	apte	er 3 Results and Analysis ······	24
1	Н	ighly pathogenic virus preparation ·····	24
	1.1	Mice-daptability virus preparation	24
	1.2	High titer virus preparation	25
	1.3	RSVvirus standardization	27
2	B	uilding of different week-old BALB/c mice model······	28
	2.1	General situation of mice	28
	2.2	weight loss ·····	29
	2.3	Nose virus titer ·····	30
	2.4	Lung virus titer	31
1	2.5	Lun tissue pathological examination	32
	2.6	Immunohistochemistry detection of lung	34
3	B	uilding of nude mice model······	37
	3.1	General situation and weight change	38
	3.2	Comparison of nose virus titer between BALB/c and nude mice \cdots	39
	3.3	Comparison of lung virus titer between BALB/c and nude mice \cdots	40
	3.4	Comparison of pathology between BALB/c and nude mice	41
	3.5	Immunohistochemistry detection of BALB/c and nude mice	42
4	A	pplication of RSV BALB/c mice model	44

Ζ	4.1 General situation and weight change	
Ζ	4.2 Nose virus titer detection ······	
Z	4.3 Lung virus titer detection ······	
Z	4.4 Pathological examination of lung tissue	
Ζ	4.5 Immunohistochemistry detection of lung tissue	
Cha	apter 4 Discussion ·····	52
1	The high titer virus preparation should be a prerequisite for	or the
building	g of RSV mice model ······	52
2	The significance of the building of different week-old BALB	/c mice
model o	of RSV infection ······	
3	Building mude mice model to study the innate immune fucti	on of
RSV inf	fection ·····	53
4	Prophylactics evaluation of 5C4 antibody on different week	-old
BALB/c	c mice ·····	54
5	Feasibility of using mice model to evaluate antibody and the	necessity
of a var	isty of animal models ······	
Cha	apter 5 Summary and Prospect	56
1	Summary	56
2	Prospect ·····	57
Ref	erence	58
Res	earch achievements ······	72
Ack	knowlegement ······	73

摘要

人呼吸道合胞病毒(Human Respiratory SyncytiaVirus, hRSV)是全球范围内 引起下呼吸道感染主要病原体之一。其感染人群年龄分布广,新生儿与老年人是 主要高危人群。据报道,几乎所有小于2周岁婴幼儿都有RSV感染经历,婴幼 儿发病住院率高达2.5-4%。RSV引起大于65周岁的老年人感染率为3-4%,病 死率约为2%。早产儿、先天性心脏病、先天性支气管及肺发育不良、免疫缺陷 的婴幼儿RSV病死率率高达5%,造成严重的医疗负担。

RSV 无安全、有效疫苗上市,唯一获准上市的预防性 RSV 药物为中和性单抗 palivizumab (Synagis®),特异性识别 RSV 融合蛋白。Synagis 在动物体内预防 性试验的成功提示 RSV 感染动物模型的建立有助于疫苗、抗体药物的保护性研 究。RSV 感染动物模型种类繁多,如小鼠、棉鼠、雪貂、猩猩等,每种动物都 有其感染特征。其中,小鼠模型由于易获得近交系及研究用检测试剂等,最常用 于 RSV 感染研究,又以 BALB/c 小鼠应用最广;裸鼠适应性免疫系统缺陷,感 染后鼻、肺内病毒清除延迟,因此可研究先天免疫介导 RSV 引起的气道炎症应 答,模拟免疫缺陷人群 RSV 感染。

本研究建立不同周龄 BALB/c 小鼠及裸鼠模型,模拟不同易感人群 RSV 感染后症状,运用该模型对 RSV 特异性抗体进行体内预防性评估,为 RSV 药物的 开发奠定基础。首先,本论文分别选取 10 周龄、30 周龄、60 周龄 BALB/c 小鼠, 分别感染 100 µL 的 10⁷ PFU/mL、10⁸ PFU/mL 滴度的 RSV 后比较其临床症状及 病理变化。结果显示,感染 10⁸ PFU/mL 滴度的 RSV 感染后不同周龄小鼠都有明 显的体重下降;鼻、肺检测到较高滴度病毒;免疫组织化学检测抗原定位于肺泡、 支气管周围的炎症细胞胞浆;引起明显的炎症细胞浸润、肺组织病理损伤;随着 小鼠周龄的增大,RSV 感染后引起的临床症状及病理变化越严重。进一步感染 10 周龄裸鼠,旨在模拟免疫缺陷 RSV 感染症状,结果发现与 BALB/c 小鼠相比, RSV 并不能使裸鼠体重下降,但裸鼠鼻、肺内病毒滴度高、持续时间久;而裸 鼠肺炎症反应出现较 BALB/c 早,感染后第 3 天即出现明显的炎症反应,第 7 天 后炎症逐渐减轻、恢复;抗原定位在肺泡、支气管周围,以第 3 天最为明显,第

Ι

12 天鲜见有阳性铁锈色反应。说明适应性免疫缺陷裸鼠可利用天然免疫独立介导 RSV 感染引起的小鼠气道炎症。利用上述已建立好的不同周龄 BALB/c 小鼠 模型,以1129 (Synagis 的鼠源性抗体)作为对照抗体,对实验室筛选的一株特 异性针对 RSV-F 蛋白的强中和抗体 5C4 进行小鼠体内预防性评估,结果显示,5C4 与 1129 都能有效减轻 RSV 引起的体重下降;降低鼻、肺内病毒滴度;及肺 部炎症反应炎症。而 5C4 在低剂量与 1129 高剂量条件下对小鼠预防性效果一致;上述现象在不同周龄鼠呈现一致,说明 5C4 抗体在不同周龄 BALB/c 小鼠上都有 良好的预防性效果,其有效剂量为 1129 抗体的 1/10,因此可作为 RSV 预防性药 物潜在开发对象。

综上所述本论文建立不同周龄 BALB/c 小鼠、裸鼠感染动物模型,模拟不同 人群 RSV 感染临床症状及病理变化,为不同人群 RSV 感染免疫机制的深入研究 及不同年龄段相关抗体和疫苗药物的选择、评估提供依据;同时将 RSV 感染的 BALB/c 模型应用于 RSV 潜力预防性抗体的评估,为新一代 RSV 预防性药物的 开发提供有效的临床前评估平台。

关键词:呼吸道合胞病毒;动物模型;肺炎支气管炎;中和抗体预防性评估

Abstract

Respiratory syncytial virus (RSV) is one of major pathogens for lower respiratory tract infection. It has a large infected age distribution, including almost all the population from the newborn to the elderly. It is reported that almost all children under two-year old have been infected by RSV. Hospitalization of infants due to RSV infections is 2.5-4% each year. Data from a variety of studies suggests that adults over 65 years of age, the overall annual incidence of RSV illness is 3 to 4%, with an estimated a fatality rate of 5%. Also, RSV has a reported fatality rate of 5% among premature births, congenital bronchial, pulmonary dysplasia and immune deficiency individuals, causing a significant medical burden.

Yet, there is no effective RSV vaccines on the market, the only approved anti-RSV drug is a neutralizing antibody palivizumab (Palivizumab) which recognizes the RSV fusion protein. Success of palivizumab supported that the building of RSV animal model would be helpful for the protection trails of RSV vaccine and antibody drugs.

There is a various type of RSV animal model, such as mice, cotton rats, ferrets, chimpanzees and so on, each model has its own charateristics. Among them, mice model was used in study of RSV infection most commonly due to easy access to inbred and detection reagent and BALB/c mice were most widely used. As lacked the adaptive immunity and delayed pulmonary viral clearance, nude mice were always used as model to research the innate immunity reponse after RSV infection and stimulate the immunocompromised population.

Our study aimed to build different week-old BALB/c mice model and nude mice model of RSV infection, to simulate infection symptoms of different population and used these models to evaluate the prophylactic potential of RSV antibodies. First, young (10 weeks), middle aged (30 weeks) and aged (60 weeks) mice were intranasally infected with 10⁶ plaque-forming units (PFU) or 10⁷ PFU RSVA2 strains,

lung virus titer, histology and immunohistochemistry was examined, and age sensitivity was analyzed. A high-titer virus infection showed an obvious symptom. Mice trended to be more susceptible to RSV infection as the growth of age. Titers up to 10^{6.5} PFU/gram lung can be attained in 60-week-old mice. Older mice experience more weight loss. Lung histology of older mice showed more serious bronchiolitis and increased number of inflammatory cells in alveolar spaced compared with that of younger mice. Further, 10 weeks BALB/c mice and nude mice were intranasally infected with 10⁷ PFU RSVA2 strains, simulating infection symptom of immune deficiency population. Comparing with BALB/c mice, nude mice showed no weight loss, while 10^{6.5} PFU/gram virus titer was attained in nude mice at day3 and 10^{4.3}PFU/gram maintained at day20. Nude mice showed early bronchiolitis compared with that of BALB/c mice. RSV antigen located around the alveolar and broncho and detected less at day12.

Using these animal model, we aimed to evaluate prophylaxitic potential of pre-F specific antibody 5C4. It was obersvered that compared with 1129, antibody 5C4 exhibited significant advantage in the terms of prophylactic efficacy, in ech week-old group, suggesting that it is potential to be commercialized and replaces the previous product palivizumab. It showed that 5C4 and 1129 can effectively reduce weight loss, lung and nose virus titer and lung pathology induced by RSV. And 5C4 in the low dose had the similar effect with high dose of 1129. The above phenomenon could show in different ages, indicating that antibody 5C4 have a good preventive effect in different week old BALB / c mice and the effective dose is one tenth of 1129 antibody. Therefore, it can be used as RSV potential prophylaxis.

In this study, we successfully established a different week-old BALB/c mice model and nude mice model, simulating the pathology and symptom of different populations after RSV infection and providing a basis for the further study of the immune mechanism in different populations and the selection and evaluation of different age related vaccines. Also, using these animal model, we can evaluate the prophylaxitic potential of highly efficient neutralizing antibody which will serve as the platform for development of new RSV potential antibody. Key words: RSV; animal model; pneumonia and bronchitis; prophylaxitic potential evaluation

缩略词

	英文缩写	英文全称	中文全称
	hRSV	human respiratory syncytial virus	人类呼吸道合胞病毒
	RSV A2	respiratory syncytial virus strain A2	呼吸道合胞病毒 A2 株
	RSV-A	subgroup A of respiratory syncytial virus	A 亚型呼吸道合胞病毒
	RSV-B	subgroup B of respiratory syncytial virus	B亚型呼吸道合胞病毒
	FI-RSV	formalin inactivated RSV vaccine	福尔马林灭活 RSV 疫苗
	DNA	deoxyribonucleic acid	脱氧核苷酸
	RNA	ribonucleic acid	核糖核酸
	mRNA	messenger ribonucleic acid	信使核糖核酸
	G protein	glycoprotein	糖蛋白
	F protein	fusion protein	融合蛋白
	M protein	matrix protein	基质蛋白
	P protein	phosphoprotein	磷蛋白
	SH protein	small hydrophobic protein	小疏水蛋白
	L protein	large nucleoprotein	大核蛋白
	N protein	nucleoprotein	核蛋白
	EM	electron microscopy	电子显微镜
	kb	kilo base pair	千碱基对
	bp	base pair	碱基对
Ś	KD	kilo nucleotide	千道尔顿
	ddH ₂ O	ddH ₂ O	双蒸水
	PFU	plaque forming units	嗜空斑形成单位
	IgG	Immunoglobulin G	免疫球蛋白G
	mAb	monoclonal antibody	单克隆抗体
	Kan	Kanamycin	卡那霉素
	Amp	Ampicillin	氨苄西林

- PBS phosphate buffered saline
- FBS fetal bovine serum
- FDA Food and drug Administration
- HE hematoxylin-eosin staining
- IHC immunohistochemistry
- IFN- γ γ -interferon
- NPA Nasopharyngeal aspirate
- rpm Revolutions per minute
- DMSO Dimethylsulfoxide

磷酸盐溶液 胎牛血清 食品药物管理局 苏木精-伊红染色 免疫组织化学反应 γ-干扰素 鼻咽抽吸物 每分钟转速 二甲基亚砜 Degree papers are in the "Xiamen University Electronic Theses and

Dissertations Database".

Fulltexts are available in the following ways:

1. If your library is a CALIS member libraries, please log on

http://etd.calis.edu.cn/ and submit requests online, or consult the interlibrary

loan department in your library.

2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn

for delivery details.